The Brazilian Senate is discussing the regulation of weed for medical purposes
Two days ago, the Brazilian Federal Senate held a public hearing on medical cannabis. Brazil's health regulatory agency (Anvisa) puts the issue of legalization on the agenda, and the House of Representatives Committee on Social Security also brings the debate to the plenary. The Commission for Human Rights and Participatory Legislation in Brazil (CCH) has scheduled this public hearing on the regulation, enforcement and taxation of cannabis for medical purposes and industrial hemp.
The idea is to establish a comprehensive standard for medical cannabis and industrial hemp in Brazil, based on the legislation in force in the US states and in Uruguay.
Convened by the MP Eduardo Costa the members present at the meeting were numerous: The Minister of Citizenship, Osmar Terra , who spoke before the Senate Committee on Human Rights and Participatory Legislation, as well as Carlos Gourlart , representative of the Ministry of Agriculture, William Dib , President of the National Agency for Health Surveillance, Leandro Ramires , representative of the Brazilian Association of Patients Suffering from Medicinal Cannabis (Ama + ME), Rodrigo Mesquita , Reforma lawyer, Legal Network for Drug Policy Reform, Carlos Vital Côrrea Lima , President of the Federal Council of Medicine (CFM) and Ricardo Ferreira, Representative of the Brazilian Society of Cannabis Studies.
Annvisa to regulate medicinal cannabis production until November
Dr William Dib (doctor and politician) said on Tuesday that the agency is expected to legislate the production, cultivation, importation and transport of cannabis for medicinal use until November 2019. The public consultation will last until August 20. . After that, Anvisa will compile the suggestions within 30-40 days. The body will then vote on the proposed regulation.
Currently, only patients with judicial authorization can produce or import cannabis products for therapeutic purposes. Decisions are individual for each patient. With regulation, production and import will be accessible to other patients.
Anvisa is not discussing recreational use and drug release, we are only discussing medical use.